Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2009 Feb 14;15(6):753-5.
doi: 10.3748/wjg.15.753.

Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients

Rebecca Pastor  1 , Francois Habersetzer, Samira Fafi-Kremer, Michel Doffoel, Thomas-F Baumert, Jean-Pierre Gut, Francoise Stoll-Keller, Evelyne Schvoerer
Affiliations
Case Reports

Hepatitis B virus mutations potentially conferring adefovir/tenofovir resistance in treatment-naive patients

Rebecca Pastor et al. World J Gastroenterol. .

Abstract

Anti-hepatitis B virus (HBV) therapy leads to the emergence of mutant viral strains during the treatment of chronic hepatitis B with nucleos(t)ides analogues. The existence of HBV variants with primary antiviral resistance may be important for treatment choice. We studied two patients with chronic HBV infection by sequencing the HBV polymerase gene. They had adefovir- and tenofovir-related mutations in the viral polymerase, although they had never been treated. These mutations were rtV214A/rtN238T in one patient and rtA194T in the other. Thus, mutations in untreated patients deserve cautious surveillance. These data indicate that mutations that can theoretically confer adefovir or tenofovir resistance may emerge in treatment-naive patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pallier C, Castéra L, Soulier A, Hézode C, Nordmann P, Dhumeaux D, Pawlotsky JM. Dynamics of hepatitis B virus resistance to lamivudine. J Virol. 2006;80:643–653. - PMC - PubMed
    1. Durantel D, Brunelle MN, Gros E, Carrouée-Durantel S, Pichoud C, Villet S, Trepo C, Zoulim F. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J Clin Virol. 2005;34 Suppl 1:S34–S43. - PubMed
    1. Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, Bonovas S, Esteban R. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients. J Hepatol. 2007;47:366–372. - PubMed
    1. Delaney WE, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50:2471–2477. - PMC - PubMed
    1. Wai CT, Fontana RJ. Clinical significance of hepatitis B virus genotypes, variants, and mutants. Clin Liver Dis. 2004;8:321–352, vi. - PubMed

Publication types